October 26, 2016 11:29 AM EDT
Pharma

Au­ven Ther­a­peu­tics sells PhI­II dry eye dis­ease drug to Sun for $40M-plus

John Carroll

Editor & Founder

Au­ven Ther­a­peu­tics has sold world­wide rights to its Phase III dry eye dis­ease ther­a­py — dubbed Seciera — to In­dia’s Sun Phar­ma for $40 mil­lion plus un­spec­i­fied …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

A service from the Financial Times